CHICAGO — The increasing news coverage of gastrointestinal conditions and their treatments have spurred the spread of misinformation, especially concerning the use of MiraLAX for treating constipation, according to a recent presentation at the AAP 2017 National Conference & Exhibition.

Concern about the use of MiraLAX began when a select group of parents noticed neuropsychiatric and behavioral changes, including aggression, tremors and obsessive-compulsive behaviors, in their children after use. They attribute these effects to a compound found within the drug: polyethylene glycol 3350 (PEG 3350).